PTX receives expanded Orphan Drug Designation for all T-cell lymphomas
Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation...
Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation...
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy...
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by...
ASX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement...
ASX-listed biotech Prescient Therapeutics is crossing a major inflection point on the back of three...
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell...
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named...
Australian biotechnology company Prescient Therapeutics is enrolling up to 12 new patients for the next...
Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in...
A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.